{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-047842","form_type":"8-K","ticker":"INBS","cik":"0001725430","company_name":"INTELLIGENT BIO SOLUTIONS INC.","filed_at":"2024-11-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.373835+00:00","generated_at":"2026-05-29T17:56:34.574104+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"INBS fingerprint drug test achieves 94.1% accuracy; FDA submission on track for Q4 2024","bullets":["Method comparison study with 135 donors and 9 operators shows 94.1% accuracy, 82.2% sensitivity, 100% specificity for opiate detection.","FDA 510(k) submission expected in Q4 2024; includes data from PK study and method study.","System components evaluated: Drug Screening Cartridge, Reader, and Fingerprint Collection Kit.","CEO Harry Simeonidis states results reaffirm accuracy and reliability for workplace drug testing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-047842","json":"https://secwatch.observer/filing/0001493152-24-047842.json","markdown":"https://secwatch.observer/filing/0001493152-24-047842.md","text":"https://secwatch.observer/filing/0001493152-24-047842.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725430/000149315224047842/0001493152-24-047842-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725430/000149315224047842/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T17:56:34.574104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}